Trial · NCT05438875
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
NCT05438875, Phase 3, Completed, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9. Trials, record NCT05438875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05438875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
- NCT number
- NCT05438875
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 96 participants, actual
- Lead sponsor
- Peking University People's Hospital
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- all-trans retinoic acid, Eltrombopag
- First posted
- 2022-06-30
- Last updated
- 2025-09-09
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sustained Response Rate (SR) at 18 months | 18 months | The maintenance of platelet count ≥ 30 x 10\^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 18-month follow-up |
| Secondary | Complete response rate (CR) | 18 months | The complete response (CR) was defined as platelet count more than 100×10\^9/L and absence of bleeding. |
| Secondary | Response rate (R) | 18 months | The Response rate (R) was defined as platelet count more than 30×10\^9/L and more than 2 times higher than baseline, without bleeding |
| Secondary | Inefficiency (NR) | 18 months | Platelet count \<30×10\^9/L, or less than 2-fold increase from baseline or associated with bleeding |
| Secondary | Recurrence rate (relapse) | 18 months | After the treatment is effective, the platelet count drops below 30×10\^9/L or drops to less than 2 times the basal value, or bleeding symptoms occur |
| Secondary | Early response | 1 week | Platelet count ≥30×10\^9/L and at least doubling baseline at 1 wk. |
| Secondary | Initial response | 1 month | Initial response as platelet count more than 30×10\^9/L and at least 2-fold increase of the baseline count and absence of bleeding. |
| Secondary | Time to response (TTR) | 18 months | The time from starting treatment to time of achievement of CR or R |
| Secondary | Time to relapse (duration of efficacy) | 18 months | The time from achievement of CR or R to time of relapse |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42517709 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05438875
GET https://conductscience.org/api/trials/v1/NCT05438875/registered